Neurocrine Biosciences, Inc. $NBIX Position Decreased by Boone Capital Management LLC

Boone Capital Management LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,815 shares of the company’s stock after selling 14,599 shares during the period. Neurocrine Biosciences comprises 7.2% of Boone Capital Management LLC’s portfolio, making the stock its 6th largest holding. Boone Capital Management LLC’s holdings in Neurocrine Biosciences were worth $21,532,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Huntington National Bank boosted its holdings in shares of Neurocrine Biosciences by 12.6% in the fourth quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after acquiring an additional 76 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of Neurocrine Biosciences by 3.1% in the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after acquiring an additional 78 shares in the last quarter. Motley Fool Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 4.8% in the fourth quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after buying an additional 78 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in Neurocrine Biosciences by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock worth $1,111,000 after acquiring an additional 80 shares during the period. Finally, Signaturefd LLC grew its holdings in Neurocrine Biosciences by 4.5% during the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock worth $273,000 after acquiring an additional 83 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity

In related news, insider Ingrid Delaet sold 2,261 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31. Following the sale, the insider owned 16,225 shares of the company’s stock, valued at approximately $2,542,619.75. The trade was a 12.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the sale, the director directly owned 15,860 shares in the company, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 355,234 shares of company stock valued at $55,330,060 in the last quarter. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Piper Sandler increased their price objective on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, June 2nd. They set a “buy” rating and a $213.00 target price on the stock. Sanford C. Bernstein assumed coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They set an “outperform” rating and a $221.00 target price on the stock. Finally, Citigroup boosted their target price on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.52.

Neurocrine Biosciences Trading Up 1.6%

NBIX stock opened at $159.00 on Thursday. The company has a market cap of $15.99 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.17 and a beta of 0.40. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $169.57. The company’s 50-day moving average price is $147.48 and its 200 day moving average price is $140.68.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.